Article
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Oncology - 1 Jan 2015
Sugimoto Kayo, Kim Soo Ryang, Kim Soo Ki, Imoto Susumu, Tohyama Madoka, Kim Ke Ih, Ohtani Aya, Hatae Takashi, Yano Yoshihiko, Kudo Masatoshi, Hayashi Yoshitake
Abstract excerpt
OBJECTIVES: The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC). The levels of alanine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.